ALLK Live signaler | Maksimer profitt med Getagraph.com

SELG 115694 min ago

@ $1.285

Utstedt: 14 feb 2024 @ 19:34

Avkastning: -9.73%

Forrige signal: feb 14 - 16:47

Forrige signal: Kjøp

Avkastning: 4.47 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	177 165
Gjennomsnittsvolum	608 693
Markedsverdi	102.71M
EPS	$0 ( 2024-03-18 )
Neste inntjeningsdato	( $-0.410 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.00400 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Radford Harlan Baird	Sell	32 142	Common Stock
2024-03-05	Tomasi Adam	Sell	47 392	Common Stock
2024-03-04	Alexander Robert	Sell	70 910	Common Stock
2024-02-16	Radford Harlan Baird	Buy	900 000	Stock Option (Right to buy)
2024-02-16	Lee Chin Hyok	Buy	500 000	Stock Option (Right to buy)

INSIDER POWER
57.98
Last 96 transactions
Buy: 11 461 350 \| Sell: 2 630 713

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: 0.98 (very strong)

Signal:(77.908) Expect same movement, but be aware

Allakos Inc Korrelasjon

10 Mest positive korrelasjoner
DSKE	0.963
NAKD	0.963
EXFY	0.962
TCDA	0.961
ALGT	0.958
BNR	0.958
CMBM	0.958
BZFD	0.956
ALRS	0.956
PODD	0.955

10 Mest negative korrelasjoner
ALTR	-0.957
NVDA	-0.954
GPACU	-0.952
PRDO	-0.95
PESI	-0.95
OHAA	-0.95
RAM	-0.948
CCRC	-0.948
SENEA	-0.946
MMYT	-0.945

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Allakos Inc Korrelasjon - Valuta/Råvare

-0.04
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.40
( neutral )

Allakos Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-6.14M (0.00 %)
EPS:	$-2.14

FY	2023
Omsetning:	$0
Bruttogevinst:	$-6.14M (0.00 %)
EPS:	$-2.14

FY	2022
Omsetning:	$0
Bruttogevinst:	$-9.98M (0.00 %)
EPS:	$-5.02

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-5.01

Financial Reports:

No articles found.

Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.